Candel Therapeutics, Inc. (CADL) Stock

Candel Therapeutics, Inc. (CADL) is a Healthcare stock trading at $12.34 (as of 2026-08-20), with a market capitalization of $944.24M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for cancer patients. Its pipeline includes CAN-2409 across Phase II/III studies for pancreatic, prostate, and lung cancers and prior Phase Ib/II work in high-grade glioma, and CAN-3110 in Phase I for recurrent glioblastoma.

Understand Candel Therapeutics, Inc.: how it makes money

Candel Therapeutics develops cancer immunotherapies (its lead candidates include CAN-2409 and CAN-3110) that are in clinical trials, with progress driven by patient outcomes in those studies.

The company’s profit model is essentially binary and outcome-driven, where future value depends on clinical success across its pipeline candidates (CAN-2409 through multiple phases, and CAN-3110 in Phase I).

Business quality (Weak): Clinical stage biotech with multiple late-breaking outcome metrics reported for CAN-2409 across several cancer settings, but meaningful uncertainty remains because key programs are still in trial phases (Phase II and Phase III for CAN-2409, Phase I for CAN-3110).

Bull case

  • Clinical outcomes reported for CAN-2409 in multiple indications: The company reports outcome metrics such as Prostate Cancer Recurrence or Death Risk Reduction for CAN-2409 Treatment Arm (30.0 percent) and Pathological Complete Response Rate (Two-Year Post-Treatment Biopsies) for CAN-2409 Plus Valacyclovir (80.4 percent).
  • Signals of durability and differentiation in reported study metrics: Reported metrics include Disease-Free Survival Hazard Ratio (0.7) and Disease-Free Survival P-Value (0.02), alongside overall survival and survival-beyond-24-month metrics for other settings.

Bear case

  • Ongoing development risk across trial phases: CAN-2409 is in Phase II and Phase III for different cancers, and CAN-3110 is in Phase I, so results still depend on continued clinical progress.
  • Safety and efficacy must remain balanced as programs advance: Reported Treatment-Related Serious Adverse Events incidence is 1.7 percent for CAN-2409 plus standard of care versus 2.2 percent for placebo plus standard of care, and efficacy signals must hold under future trial conditions.
Valuation — source: SEC EDGAR (first-party)
Price$12.34
Market Cap$944.24M
Price / Book7.49
Price / Sales639.30
FCF Yield-5.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$2.08M
Net Margin-1823.1%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($53.84M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOPaul-Peter Tak
Employees38
CountryUS
IPO Date2021-07-27

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Vor Biopharma Inc. (VOR)
  • Odyssey Therapeutics, Inc. (ODTX)
  • Sana Biotechnology, Inc. (SANA)
  • Solid Biosciences Inc. (SLDB)
  • 4D Molecular Therapeutics, Inc. (FDMT)
  • Aura Biosciences, Inc. (AURA)
  • Allogene Therapeutics, Inc. (ALLO)
  • Tectonic Therapeutic, Inc. (TECX)
CADL earnings history · CADL institutional & insider holders · CADL KPIs & operating metrics · CADL financials · CADL investor presentations & press releases · CADL SEC filings · CADL peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.